AstraZeneca May Have Knocked One Out of the Park
AstraZeneca (NYSE: AZN) recently impressed a crowd of oncologists at the annual San Antonio Breast Cancer Symposium with surprisingly good clinical trial results. In a nutshell, it looks like an experimental drug that the company licensed from Daiichi Sankyo (OTC: DSNKY) could become a great new option that works where others have failed.
Some analysts think annual sales of the drug, trastuzumab deruxtecan, could top out above $7 billion, but there are potential hazards on the road to blockbuster sales. Here's what you should know before buying any shares of the giant pharmaceutical company.
Image source: Getty Images.
Source Fool.com
